vascular endothelial growth factor news

Merck to buy rights to Chinese cancer drug

Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate called LM-299 from LaNova. Read more here.

Reuters on MSN · 20h

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,

Bloomberg L.P. · 20h

Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.

STAT · 17h

Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company

GlobalData on MSN23h

BioNTech signs agreement to acquire Biotheus

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Medscape2d

Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMD

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his ...

Nature1y

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy

At about the same time, seminal observations implicating blood-vessel growth in intraocular disorders ... that a diffusible factor (named afterward 'factor X') could be responsible not only ...

GEN10d

Wet AMD Treatments Could Work Better If Both VEGF and ANGPTL4 Are Targeted

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

The Manhattan Mercury10d

Why Treatments Can Fail Folks With 'Wet' Macular Degeneration -- and What Might Really Work

To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...

GlobalData on MSN7d

Minghui Pharmaceutical’s MHB039A shows promise in Phase I trial for solid tumours

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

Finance News Network19h

Eye on the prize: $15.9m boost for Opthea's vision impairment therapy

Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...

BuzzHint on MSN3mon

Breakthrough in Male Pattern Baldness: Natural Sugar Sparks Hope for Hair Regrowth

The researchers appear to believe that 2dDR up-regulates vascular endothelial growth factor required for new hair ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results